Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ: ACAD )

19.00 -0.01 (-0.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,292,450
Open 19.08
Bid (Size) 18.85 (1)
Ask (Size) 19.00 (1)
Prev. Close 19.01
Today's Range 18.93 - 19.65
52wk Range 14.15 - 26.56
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Earnings Scheduled For February 26, 2025
Via Benzinga

Performance

YTD
+1.82%
+1.82%
1 Month
+4.00%
+4.00%
3 Month
+16.64%
+16.64%
6 Month
+21.02%
+21.02%
1 Year
-27.92%
-27.92%

More News

Read More
NASDAQ:ACAD, an undervalued stock with good fundamentals.
Via Chartmill
While growth is established for NASDAQ:ACAD, the stock's valuation remains reasonable.
Via Chartmill
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet
Via Benzinga
Exposures Fossil Fuels
Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
From Acadia Pharmaceuticals
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Via MarketBeat
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.